Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Bio-Rad Laboratories, Inc.: Strengths and Weaknesses

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Bio-Rad Laboratories, Inc.
  • The company is in a robust financial situation considering its net cash and margin position.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses: Bio-Rad Laboratories, Inc.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • With an expected P/E ratio at 44.32 and 43.33 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

Bio-Rad Laboratories, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

Bio-Rad Laboratories, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Bio-Rad Laboratories, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Bio-Rad Laboratories, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Bio-Rad Laboratories, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
10.02B
BBB
-
182B
BBB
118B
BBB
61.7B
AA
50.55B
AAA
48.98B
A
31.65B
BBB
29.87B
A
23.71B
AAA
21.78B
AA
Average 57.79B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. BIO Stock
  4. Ratings Bio-Rad Laboratories, Inc.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!